Truist Financial Corp Purchases 2,420 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Truist Financial Corp grew its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 20.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 14,217 shares of the company’s stock after acquiring an additional 2,420 shares during the period. Truist Financial Corp owned about 0.05% of Castle Biosciences worth $310,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Castle Biosciences by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 1,494,176 shares of the company’s stock worth $33,096,000 after acquiring an additional 32,695 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Castle Biosciences by 8.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 809,934 shares of the company’s stock worth $17,631,000 after buying an additional 60,675 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Castle Biosciences by 47.3% during the second quarter. Renaissance Technologies LLC now owns 301,500 shares of the company’s stock valued at $6,564,000 after acquiring an additional 96,800 shares in the last quarter. Acadian Asset Management LLC increased its stake in Castle Biosciences by 33.0% during the 2nd quarter. Acadian Asset Management LLC now owns 280,497 shares of the company’s stock valued at $6,101,000 after purchasing an additional 69,673 shares in the last quarter. Finally, Marshall Wace LLP increased its position in shares of Castle Biosciences by 116.5% during the second quarter. Marshall Wace LLP now owns 212,036 shares of the company’s stock valued at $4,616,000 after acquiring an additional 114,104 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Insider Buying and Selling at Castle Biosciences

In other news, COO Kristen M. Oelschlager sold 12,989 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $23.06, for a total value of $299,526.34. Following the transaction, the chief operating officer now owns 132,836 shares in the company, valued at $3,063,198.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, COO Kristen M. Oelschlager sold 12,989 shares of Castle Biosciences stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $23.06, for a total transaction of $299,526.34. Following the transaction, the chief operating officer now directly owns 132,836 shares in the company, valued at approximately $3,063,198.16. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Kristen M. Oelschlager sold 2,793 shares of the business’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $22.06, for a total value of $61,613.58. Following the sale, the chief operating officer now directly owns 145,825 shares of the company’s stock, valued at $3,216,899.50. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 45,476 shares of company stock worth $1,181,637 in the last three months. 7.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

CSTL has been the topic of several analyst reports. BTIG Research upped their price objective on Castle Biosciences from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Stephens restated an “overweight” rating and issued a $37.00 price target on shares of Castle Biosciences in a research note on Tuesday, August 6th. Finally, Robert W. Baird increased their price objective on Castle Biosciences from $34.00 to $37.00 and gave the company an “outperform” rating in a research report on Tuesday, August 6th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $34.00.

Castle Biosciences Trading Down 1.3 %

NASDAQ:CSTL opened at $32.64 on Friday. The company has a market cap of $901.09 million, a PE ratio of -28.38 and a beta of 1.03. The company has a current ratio of 8.12, a quick ratio of 7.92 and a debt-to-equity ratio of 0.02. The company has a 50 day simple moving average of $29.52 and a two-hundred day simple moving average of $24.57. Castle Biosciences, Inc. has a 12 month low of $12.23 and a 12 month high of $34.50.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.47. Castle Biosciences had a negative return on equity of 0.77% and a negative net margin of 1.08%. The company had revenue of $87.00 million during the quarter, compared to analyst estimates of $69.95 million. During the same quarter in the previous year, the company posted ($0.70) earnings per share. Research analysts forecast that Castle Biosciences, Inc. will post -0.58 earnings per share for the current year.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.